Posted by mayonewsreleases (@mayonewsreleases) · May 6, 2013
Mayo Clinic Research at The Association for Research in Vision and Ophthalmology, 2013
Mayo Clinic ophthalmology researchers will be well represented at The Association for Research in Vision and Ophthalmology (ARVO) 2013, with 25 presentations and posters, including five papers over the five days of the conference. ARVO will hold its annual meeting from May 5-9 in Seattle.
Jonathan Holmes, M.D. and colleagues are presenting a paper on the health-related quality of life after being treated with a prism for diplopia (double vision). Results show successful prism treatment in 67 percent of the 36 patients involved in the study, with improvements in general function and reading function. (Monday, May 6, 8:30 a.m. PT)
Sanjay Patel, M.D. and colleagues compared changes in the corneal endothelium after three different keratoplasty techniques. Studying outcomes after penetrating keratoplasty, deep lamellar endothelial karatoplasty, and Descemet-stripping endothelial karatoplasty, they found that after three years cell loss was less with the Descemet-stripping procedure. (Monday, May 6, 11 a.m. PT).
Aarika Menees, M.D., and colleagues used laser micro-dissection, and chromatography-based tandem mass spectrometry to study protein deposits in stromal corneal dystrophies and to find novel mutations. Their findings point to a distinct mechanism for two types of corneal dystrophy. (Wednesday, May 8, 11 a.m. PT).
Keith Baratz, M.D. and colleagues from Mayo Clinic, Duke University and UC-San Diego used genomic screening to study possible associations between the trinucleotide(TGC) on the transcription factor 4 gene and the risk of developing Fuchs endothelial corneal dystrophy. (Wednesday, May 8, 11 a.m. PT).
Sarah Hatt and others have explored possible associations between health-related quality of life and depression/distress factors in patients being treated for strabismus. They found a correlation with subclinical depression in these patients that they say should be considered when evaluating patient-reported outcomes and further treatment. (Thursday May 9, 10:30 a.m. PT).
For interviews or to follow up on any of these studies or any stories relating to eye conditions or disease, contact Bob Nellis at 507-284-5005.